Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bisoxatin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoxatin is a stimulant laxative used primarily for the treatment of constipation and for preparation of the colon prior to surgical procedures. It acts by increasing peristalsis (the wave-like muscle contractions that move food through the digestive tract) and inhibiting the absorption of water and ions in the intestine, resulting in increased water content in feces and enhanced bowel movement. The precise molecular mechanism underlying its stimulant effect is not fully understood. Bisoxatin is classified as a diarylmethane derivative and is administered orally. It has been marketed under brand names such as Wylaxine and Laxonalin, particularly in Belgium[1][3][4][5][6].
- Brand names
- WylaxineLaxonalin
- Other names
- BisoxatinaBisoxatineBisoxatinum
Beyond the preview
Go deeper on Bisoxatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bisoxatin.